Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk


 

FROM THE AACR ANNUAL MEETING

Pelvic inflammatory disease caused by chlamydia appears to significantly increase the risk of ovarian cancer, according to research to be presented at the annual meeting of the American Association for Cancer Research.

The finding, replicated in two large databases, suggests that promptly treating the infection might reduce the lifetime risk of developing ovarian cancer, Britton Trabert, PhD, said during a press briefing held in advance of the meeting.

Dr. Britton Trabert, National Cancer Institute, Bethesda, Md.

Dr. Britton Trabert

“Although these findings need to be replicated, they suggest potential ovarian cancer risk reduction through targeted treatment of chlamydia infections,” said Dr. Trabert, the Earl Stadtman Investigator at the National Cancer Institute.

The study portends both promise and challenge, according to Elaine R. Mardis, PhD, who comoderated the session.

Pages

Recommended Reading

HIPEC shows survival benefit for advanced ovarian cancer
MDedge ObGyn
Approach to the asymptomatic adnexal mass: When to operate, refer, or observe
MDedge ObGyn
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge ObGyn
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
MDedge ObGyn
USPSTF: Routine screens for ovarian cancer not recommended
MDedge ObGyn
FDA approves new HPV assay
MDedge ObGyn
Telling her she has cancer: A patient-centered approach to breaking bad news
MDedge ObGyn
2018 Update on gynecologic cancer
MDedge ObGyn
Avelumab safety compares with other checkpoint inhibitors
MDedge ObGyn
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge ObGyn